Steven Rose, MD
Retina Specialist · Rochester, NYNPI 1174502652
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $3,995 of the $5,264 with a category attached, or 75.9%. US Retina LLC accounts for 75.9% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $1,643 and has fallen 93.4% since, to $109 in 2025.
Across 41 payments — averaging $128.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$4K
- Regeneron Healthcare Solutions, Inc.$343
- Apellis Pharmaceuticals, Inc.$136
- Genentech USA, Inc.$135
- Eyepoint US, Inc.$128
- Hoffmann-la Roche Limited$125
- plus $402 from 8 others
Across 49 payments — averaging $2855.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$93K
- AbbVie$34K
- Novartis$7K
- Roche TCRC, Inc.$6K
What the payments were for
- Food & beverage$1,20923%
- Education$591%
- Ownership interest$3,99576%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $3,995 |
| Regeneron Healthcare Solutions, Inc. | 10 | $343 |
| Apellis Pharmaceuticals, Inc. | 3 | $136 |
| Genentech USA, Inc. | 7 | $135 |
| Eyepoint US, Inc. | 2 | $128 |
| Hoffmann-la Roche Limited | 1 | $125 |
| Boston Scientific | 1 | $119 |
| Bausch & Lomb Americas Inc. | 1 | $89 |
| Novartis | 3 | $51 |
| AbbVie | 2 | $37 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $35 |
| Neurotech Pharmaceuticals, Inc. | 1 | $35 |
| Astellas Pharma US Inc | 1 | $23 |
| Alimera Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$125
- GENERAL VASCULAR INTERVENTION$119
- EYLEA$106
- YUTIQ$105
- Syfovre$103
How this compares
$5,264 in reported general payments places this provider in the 65th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 20 | $676 |
| Tobramycin | 12 | $51 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Rochester
- Matthew WitmerRochester$62K
- Edward HallRochester$38K
- Brian ConnollyRochester$7K
- Vikas KhetanRochester$3K
- Sana IdreesRochester$2K
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.